An official website of the United States government Here's how you know

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Drugs@FDA: FDA-Approved Drugs

Home | Previous Page

Abbreviated New Drug Application (ANDA): 202385
Company: AMNEAL PHARMS

Products on ANDA 202385

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	TE Code	RLD	RS
FELBAMATE	FELBAMATE	600MG/5ML	SUSPENSION;ORAL	Prescription	AB	No	No

Approval Date(s) and History, Letters, Labels, Reviews for ANDA 202385

Original Approvals or Tentative Approvals

Action Date	Submission	Action Type	Submission Classification	Review Priority; Orphan Status	Letters, Reviews, Labels, Patient Package Insert	Notes	Url
12/16/2011	ORIG-1	Approval			Letter (PDF)	Label is not available on this site.	https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2011/202385s000ltr.pdf

Therapeutic Equivalents for ANDA 202385

FELBAMATE

SUSPENSION;ORAL; 600MG/5ML
TE Code = AB

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	RLD	TE Code	Application No.	Company
FELBAMATE	FELBAMATE	600MG/5ML	SUSPENSION;ORAL	Prescription	No	AB	202385	AMNEAL PHARMS
FELBAMATE	FELBAMATE	600MG/5ML	SUSPENSION;ORAL	Prescription	No	AB	211333	NOVITIUM PHARMA
FELBAMATE	FELBAMATE	600MG/5ML	SUSPENSION;ORAL	Prescription	No	AB	206314	TARO

Top